145 related articles for article (PubMed ID: 31593141)
1. Coexistence of Fabry disease with IgM nephropathy: A case report.
Wu H; Behera TR; Gong J; Shen Q
Medicine (Baltimore); 2019 Oct; 98(41):e17566. PubMed ID: 31593141
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of Fabry disease and IgA nephropathy: a report of two cases.
Yin G; Wu Y; Zeng CH; Chen HP; Liu ZH
Ir J Med Sci; 2014 Dec; 183(4):671-5. PubMed ID: 24913738
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological characteristics of Fabry disease combined with IgA nephropathy in Chinese patients
.
Yang N; Wang X; Xu F; Zeng C; Wang J; Liu Z
Clin Nephrol; 2017 Apr; 87 (2017)(4):188-195. PubMed ID: 28157068
[TBL] [Abstract][Full Text] [Related]
4. A case of female Fabry disease revealed by renal biopsy.
Aratani S; Yamakawa H; Suzuki S; Otsuka T; Sakai Y; Shimizu A; Tsuruoka S
CEN Case Rep; 2020 Feb; 9(1):24-29. PubMed ID: 31542871
[TBL] [Abstract][Full Text] [Related]
5. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
6. Hemizygous Fabry disease associated with membranous nephropathy: A rare case report
.
Zhou W; Ni Z; Zhang M
Clin Nephrol; 2018 Sep; 90(3):227-231. PubMed ID: 29792392
[TBL] [Abstract][Full Text] [Related]
7. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
8. Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report.
Kanai T; Ito T; Aoyagi J; Yamagata T
Medicine (Baltimore); 2022 Feb; 101(7):e28830. PubMed ID: 35363176
[TBL] [Abstract][Full Text] [Related]
9. A case of latent heterozygous Fabry disease in a female living kidney donor candidate.
Minami M; Mizuma E; Nakahara M; Oda Y; Yoshimine H; Tokunaga K; Mitsuke A; Yamada Y; Enokida H; Masutani K; Goto N; Ido A
CEN Case Rep; 2021 Feb; 10(1):30-34. PubMed ID: 32712909
[TBL] [Abstract][Full Text] [Related]
10. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
11. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
12. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
Fogo AB; Bostad L; Svarstad E; Cook WJ; Moll S; Barbey F; Geldenhuys L; West M; Ferluga D; Vujkovac B; Howie AJ; Burns A; Reeve R; Waldek S; Noël LH; Grünfeld JP; Valbuena C; Oliveira JP; Müller J; Breunig F; Zhang X; Warnock DG;
Nephrol Dial Transplant; 2010 Jul; 25(7):2168-77. PubMed ID: 19833663
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
14. Hemizygous Fabry disease associated with IgA nephropathy: a case report.
Shimohata H; Yoh K; Takada K; Tanaka H; Usui J; Hirayama K; Kobayashi M; Yamagata K
J Nephrol; 2009; 22(5):682-4. PubMed ID: 19810002
[TBL] [Abstract][Full Text] [Related]
15. Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.
Fall B; Scott CR; Mauer M; Shankland S; Pippin J; Jefferson JA; Wallace E; Warnock D; Najafian B
PLoS One; 2016; 11(12):e0168346. PubMed ID: 27992580
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of Fabry Disease and Membranous Nephropathy.
Liu Y; Xie H; Lin H; Chen S; Wang W; Zhao G; Zhang X
Iran J Kidney Dis; 2016 Jan; 10(1):48-50. PubMed ID: 26837682
[TBL] [Abstract][Full Text] [Related]
17. A case of Fabry nephropathy with histological features of oligonephropathy.
Nishida M; Kosaka K; Hasegawa K; Nishikawa K; Itoi T; Tsukimura T; Togawa T; Sakuraba H; Hamaoka K
Eur J Pediatr; 2014 Aug; 173(8):1111-4. PubMed ID: 23913314
[TBL] [Abstract][Full Text] [Related]
18. AJKD Atlas of Renal Pathology: Fabry nephropathy.
Najafian B; Fogo AB; Lusco MA; Alpers CE
Am J Kidney Dis; 2015 Nov; 66(5):e35-6. PubMed ID: 26498420
[No Abstract] [Full Text] [Related]
19. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
20. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
Najafian B; Svarstad E; Bostad L; Gubler MC; Tøndel C; Whitley C; Mauer M
Kidney Int; 2011 Mar; 79(6):663-670. PubMed ID: 21160462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
